BASEL (dpa-AFX) - Genmab A/S (GMXAY.PK, GNMSF.OB) said that its
collaboration partner Novartis will start Phase III studies of the subcutaneous
formulation of ofatumumab in relapsing multiple sclerosis or MS with enrolment
of patients expected to...
MorphoSys has initiated legal action against Genmab and Johnson & Johnson's Janssen Biotech. The case relates to Darzalex, Genmab and Janssen's multiple myeloma drug that MorphoSys claims infringes on its patent covering antibodies with certain...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.